methenamine mandelate profile

Methenamine mandelate is a urinary antiseptic medication used to treat urinary tract infections. It works by releasing formaldehyde in the acidic environment of the urine, which has antibacterial properties. Methenamine mandelate is typically used for long-term prevention of urinary tract infections, especially in people with recurrent infections or who are at high risk of developing infections. The medication is often used in combination with other antibiotics. Methenamine mandelate is synthesized by reacting methenamine with mandelic acid. The resulting compound is a white, crystalline powder that is readily soluble in water. Research on methenamine mandelate focuses on its efficacy in treating urinary tract infections, its potential side effects, and its interactions with other medications. The compound is generally well-tolerated, but can cause some side effects, such as nausea, vomiting, and abdominal pain. Methenamine mandelate should be used with caution in people with kidney disease, as it can accumulate in the body and cause toxicity.'

methenamine mandelate: 'Reflux' is Dagra brand name which is not kept as term due to low use and other meanings of the term [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11478
CHEMBL ID	3833312
SCHEMBL ID	3645
MeSH ID	M0079831

Synonyms (74)

Synonym
methenamine mandelate
mandelate, hexamethylenetetra-amine-
hexamethylenetetramine mandelate
587-23-5
D00856
mandelamine (tn)
hexamine mandelate (jan)
methenamine mandelate (usp)
AKOS024319335
mandelic acid, compd with hexamethylenetetramine
einecs 229-817-2
hexamethylenetetramine, mandelate
6754-75-2
benzeneacetic acid, alpha-hydroxy-, compd with 1,3,5,7-tetraazatricyclo(3.3.1.1(3,7))decane
glycolic acid, compound with 1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane
mandelic acid salt with (ch2)6n4
ai3-50130
hexamethylenetetramine phenylglycolate
uro-cedulamin
1,3,5,7-tetraazatricyclo(3.3.1.1(3,7))decane, mono(alpha-hydroxybenzeneacetate)
hexamethyleneamine mandelate
diuramine
mandoz
uronamin
mandastat
reflux
mandelic acid methenamine salt
mandopan
hexamine mandelate
prov-u-sep
mandurin
renelate
unii-695n30cinr
mandalay
cedulamin
hexamethylenetetramine monomandelate
mandural
mantropine
695n30cinr ,
einecs 209-597-4
mandacon
penelate
hexamethylenetetramine mono-(+-)-mandelate
uronamine
uromandelin
methenamine mandelate [usp]
hexydaline
FT-0603481
hexamine mandelate [jan]
methenamine mandelate [green book]
methenamine mandelate [who-dd]
methenamine mandelate [usp-rs]
hexamethylenetetramine mono-(+/-)-mandelate
methenamine mandelate [vandf]
methenamine mandelate [mart.]
hexamethylenamine mandelate
methenamine mandelate [usp monograph]
methenamine mandelate [mi]
SCHEMBL3645
CHEMBL3833312
methenamine mandelate, united states pharmacopeia (usp) reference standard
hydroxy(phenyl)acetic acid compound with 1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane (1:1)
methenaminemandelate
19442-87-6
DTXSID40941180
hydroxy(phenyl)acetic acid--1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane (1/1)
2-hydroxy-2-phenylacetic acid;1,3,5,7-tetrazatricyclo[3.3.1.13,7]decane
BCP32164
hexamethylenetetramine mandelate pound>>hexamine mandelate
Q27264316
benzeneacetic acid, alpha-hydroxy-, (+/-)-, compd. with 1,3,5,7-tetraazatricyclo((3.3.1.1(sup 3,7))decane (1:1)
methenamine mandelate (usp-rs)
methenamine mandelate (usp monograph)
methenamine mandelate (mart.)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (87.88)	18.7374
1990's	1 (3.03)	18.2507
2000's	2 (6.06)	29.6817
2010's	1 (3.03)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.03%)	5.53%
Reviews	1 (3.03%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (93.94%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis [NCT03379389]	Phase 4	284 participants (Actual)	Interventional	2018-03-31	Completed
Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs [NCT03077711]	Phase 4	92 participants (Actual)	Interventional	2016-06-30	Completed
Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study. [NCT00781625]		120 participants (Anticipated)	Interventional	2008-10-31	Recruiting
The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection [NCT02358993]		201 participants (Actual)	Interventional	2014-12-31	Completed
Methenamine Hippurate With Cranberry Capsules Versus Cranberry Capsules Alone for UTI Prevention in a Short-term Indwelling Foley Catheter Population After Urogynecological Surgery: A Double-Blinded Randomized Controlled Trial [NCT03818321]	Phase 2	185 participants (Actual)	Interventional	2019-06-17	Completed
A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain [NCT05658874]	Phase 3	80 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria [NCT01657448]	Phase 3	316 participants (Actual)	Interventional	2016-06-27	Completed
The Efficacy and Effect of Methenamine Hippurate in a Non-antibiotic, Multimodal Approach to UTI Prevention [NCT03996057]	Phase 4	0 participants (Actual)	Interventional	2018-06-20	Withdrawn(stopped due to "Project canceled due to PI leaving institution, staff changes and COVID~Project canceled for other reason , describe: - Due to staff changes and COVID~Project canceled due to PI leaving, staff changes and COVID")
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study [NCT04077580]	Phase 4	400 participants (Anticipated)	Interventional	2019-11-01	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT02358993 (5) [back to overview]	Antibiotic Resistance of Culture-positive Symptomatic UTI
NCT02358993 (5) [back to overview]	Number of Participants With Culture-positive Symptomatic UTI
NCT02358993 (5) [back to overview]	Rate of UTI Consistent With NHSN Criteria
NCT02358993 (5) [back to overview]	Treatment of Clinically Suspected UTI - Per Protocol
NCT02358993 (5) [back to overview]	Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis
NCT03077711 (5) [back to overview]	Morisky Medication Adherence Survey
NCT03077711 (5) [back to overview]	Number of Infections
NCT03077711 (5) [back to overview]	Recurrent UTI
NCT03077711 (5) [back to overview]	Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI
NCT03077711 (5) [back to overview]	Bacterial Infection Prevalence and Types
NCT03818321 (1) [back to overview]	Incidence of Urinary Track Infection (UTI)

Antibiotic Resistance of Culture-positive Symptomatic UTI

All patients who submit urine cultures that are positive will have sensitivities performed as per standard care. The prevalence of bacterial species and sensitivities will be collected (NCT02358993)
Timeframe: 3 weeks post-operative

Intervention	Participants (Count of Participants)
Methenamine	0
Ciprofloxacin	0

[back to top]

Number of Participants With Culture-positive Symptomatic UTI

All patients will be encouraged to submit urine cultures prior to treatment, but this is not always possible. Amongst patients who undergo urine culture as part of standard of care for UTI, the rate of positive cultures will be identified. (NCT02358993)
Timeframe: 3 weeks post-operative

Intervention	Participants (Count of Participants)
Methenamine	5
Ciprofloxacin	4

[back to top]

Rate of UTI Consistent With NHSN Criteria

We plan to analyze the prevalence of UTI in this population that meet the definitions of symptomatic UTI and catheter-associated UTI according to the National Healthcare Safety Network criteria. (NCT02358993)
Timeframe: 3 weeks post-operative

Intervention	Participants (Count of Participants)
Methenamine	10
Ciprofloxacin	6

[back to top]

Treatment of Clinically Suspected UTI - Per Protocol

This is defined as any symptomatic UTI requiring treatment with antibiotics as determined by the development of 2 or more of the following symptoms, in the absence of vaginal symptoms: urinary frequency; urinary urgency; dysuria; fever over 38oC/100.4oF; suprapubic, flank, or back pain; and/or chills. (NCT02358993)
Timeframe: 3 weeks post-operative

Intervention	Participants (Count of Participants)
Methenamine	12
Ciprofloxacin	12

[back to top]

Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis

Intervention	Participants (Count of Participants)
Methenamine	13
Ciprofloxacin	12

[back to top]

Morisky Medication Adherence Survey

Morisky Medication Adherence Scale-8 (MMAS-8). Patient tolerability of medications using a tolerability survey. Minimum and maximum scores are 0 and 8 respectively. 0 means no adherence and 8 is maximal adherence. Low adherence corresponds to a score less than 6, medium adherence is between 6 and <8, and 8 is high adherence. (NCT03077711)
Timeframe: up to 12 months

Intervention	units on a scale (Mean)
Patients With Recurrent UTIs Arm 1	7.28
Patients With Recurrent UTIs Arm 2	6.94

[back to top]

Number of Infections

The number of infections at a 12 month follow up time period as defined by symptoms and positive urine culture. (NCT03077711)
Timeframe: up to 12 months

Intervention	urinary tract infections (Mean)
Patients With Recurrent UTIs Arm 1	1.5
Patients With Recurrent UTIs Arm 2	1.6

[back to top]

Recurrent UTI

The number of patient who had a recurrence of UTI within 12 months (NCT03077711)
Timeframe: up to 12 months

Intervention	Participants (Count of Participants)
Patients With Recurrent UTIs Arm 1	28
Patients With Recurrent UTIs Arm 2	28

[back to top]

Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI

Patients will be advised to follow up with any symptoms of a recurrence or at 6 and 12 month intervals if symptom-free. (NCT03077711)
Timeframe: up to 12 months

Intervention	days (Mean)
Patients With Recurrent UTIs Arm 1	101
Patients With Recurrent UTIs Arm 2	119

[back to top]

Bacterial Infection Prevalence and Types

Urine cultures and sensitivities for positive urine cultures (NCT03077711)
Timeframe: up to 12 months

Intervention	infections (Number)
	Escherichia coli	Klebsiella pneumonia	Enterococcus faecalis	Extended spectrum beta lactamase Escherichia coli	Other bacteria	Strains pan sensitive to all antibiotics	Strains resistant to trimethoprim	Strains resistant to abx other than trimethoprim
Patients With Recurrent UTIs Arm 1	43	11	3	6	15	5	58	10
Patients With Recurrent UTIs Arm 2	50	6	9	9	12	20	30	29

[back to top]

Incidence of Urinary Track Infection (UTI)

Incidence of UTIs will be diagnosed at one week post-op visit. (NCT03818321)
Timeframe: From surgery to one week post-op visit, approximately 1 week post surgery

Intervention	Participants (Count of Participants)
Methenamine Hippurate With Cranberry	62
Placebo With Cranberry	71

[back to top]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	5.17	4	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
mandelic acid SAMMA: mandelic acid condensation polymer	3.03	5	0	2-hydroxy monocarboxylic acid; benzenes	antibacterial agent; human xenobiotic metabolite
methenamine Methenamine: An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173). hexamethylenetetramine : A polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms.	8.18	33	1	polyazaalkane; polycyclic cage; tetramine	antibacterial drug
nalidixic acid [no description available]	1.96	1	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	7.34	2	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfanilamide [no description available]	1.93	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	1.96	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	1.96	1	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
ninhydrin Ninhydrin: 2,2-Dihydroxy-1H-indene-1,3-(2H)-dione. Reagent toxic to skin and mucus membranes. It is used in chemical assay for peptide bonds, i.e., protein determinations and has radiosensitizing properties.. ninhydrin : A member of the class of indanones that is indane-1,3-dione bearing two additional hydroxy substituents at position 2.	1.95	1	0	aromatic ketone; beta-diketone; indanones; ketone hydrate	colour indicator; human metabolite
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	1.96	1	0	cyclic ketone; erythromycin
methenamine hippurate methenamine hippurate: both parts of molecule contribute to its antibacterial action	10.25	6	0	N-acylglycine
ammonium chloride Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.	3.75	2	1	ammonium salt; inorganic chloride	ferroptosis inhibitor
calcium oxalate Calcium Oxalate: The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi.. calcium oxalate : The calcium salt of oxalic acid, which in excess in the urine may lead to formation of oxalate calculi (kidney stones).	1.97	1	0	organic calcium salt
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	2.36	2	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
struvite Struvite: The mineral magnesium ammonium phosphate with the formula NH4MgPO4. It is associated with urea-splitting organisms in a high magnesium, high phosphate, alkaline environment. Accumulation of crystallized struvite is found in the urinary tract as struvite CALCULI and as scale on sewage system equipment and wastewater pipes.	1.97	1	0	hydrate; phosphate mineral	fertilizer
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	8.8	4	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent

Condition	Relationship Strength	Studies	Trials
Recrudescence [description not available]	3.6	3	0
Bacterial Infections, Gram-Negative [description not available]	3.01	1	0
Bacterial Infections, Gram-Positive [description not available]	3.01	1	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	6.26	14	1
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	3.01	1	0
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	3.01	1	0
Bacterial Disease [description not available]	1.93	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	1.93	1	0
Infectious Diseases [description not available]	1.93	1	0
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	1.93	1	0
Infection [description not available]	6.94	1	0
Infections, Pseudomonas [description not available]	3.74	2	1
Necrotizing Pyelonephritis [description not available]	1.94	1	0
Infections, Proteus [description not available]	2.35	2	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	6.94	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	3.74	2	1
Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.	1.94	1	0
Bladder Disorder, Neurogenic [description not available]	3.73	2	1
Urinary Bladder, Neurogenic Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.	3.73	2	1
Chronic Illness [description not available]	2.02	1	0
Varices [description not available]	2.02	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.02	1	0
Varicose Veins Enlarged and tortuous VEINS.	2.02	1	0
Bacteriuria The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.	2.88	4	0
Injuries, Spinal Cord [description not available]	2.65	3	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2.65	3	0
Bladder Diseases [description not available]	1.96	1	0
Amino Acid Metabolism Disorders, Inborn [description not available]	1.95	1	0
Kidney Stones [description not available]	1.97	1	0
Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.	1.97	1	0
Ache [description not available]	1.96	1	0
Urination Disorders Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.	1.96	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	1.96	1	0

methenamine mandelate

Description

Cross-References

Synonyms (74)

Research

Studies (33)

Market Indicators

Research Demand Index: 45.61

Study Types

Clinical Trials (10)

Trial Overview

Trial Outcomes

Antibiotic Resistance of Culture-positive Symptomatic UTI

Number of Participants With Culture-positive Symptomatic UTI

Rate of UTI Consistent With NHSN Criteria

Treatment of Clinically Suspected UTI - Per Protocol

Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis

Morisky Medication Adherence Survey

Number of Infections

Recurrent UTI

Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI

Bacterial Infection Prevalence and Types

Incidence of Urinary Track Infection (UTI)

methenamine mandelate

Description

Cross-References

Synonyms (74)

Research

Studies (33)

Market Indicators

Research Demand Index: 45.61

Study Types

Clinical Trials (10)

Trial Overview

Trial Outcomes

Antibiotic Resistance of Culture-positive Symptomatic UTI

Number of Participants With Culture-positive Symptomatic UTI

Rate of UTI Consistent With NHSN Criteria

Treatment of Clinically Suspected UTI - Per Protocol

Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis

Morisky Medication Adherence Survey

Number of Infections

Recurrent UTI

Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI

Bacterial Infection Prevalence and Types

Incidence of Urinary Track Infection (UTI)

Related Drugs (16)

Related Conditions (33)